CN Patent

CN116437902A — 包含美洛昔康的医药组成物

Assigned to Mylan Laboratories Ltd · Expires 2023-07-14 · 3y expired

What this patent protects

本发明关于用于治疗急性疼痛的包含美洛昔康的新颖医药组成物，其中该组成物包含至少一种亲水性聚合物及一种或多种碱化剂或其组合。

USPTO Abstract

本发明关于用于治疗急性疼痛的包含美洛昔康的新颖医药组成物，其中该组成物包含至少一种亲水性聚合物及一种或多种碱化剂或其组合。

Drugs covered by this patent

Patent Metadata

Patent number
CN116437902A
Jurisdiction
CN
Classification
—
Expires
2023-07-14
Drug substance claim
No
Drug product claim
No
Assignee
Mylan Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.